Effect of Concomitant Radiotherapy and Trastuzumab on Cardiotoxicity of Patients Treated for Early Breast Cancer
The investigators know from the studies, that were already published, that for HER2 positive
early breast cancer patients in adjuvant treatment concomitant radiotherapy and trastuzumab
is safe during the treatment. But there is no study with long term results of cardial
function, especially combination of Left ventricular ejection fraction (LVEF) and NT-proBNP.
Observational
Observational Model: Cohort, Time Perspective: Prospective
difference in LVEF (Left Ventricular Ejection Fraction)
we will compare LVEF (LVEF 1) measured before treatment with adjuvant Trastuzumab and concomitant Radiotherapy of breast/thoracic wall with LVEF (LVEF 2) measured at follow up (after adjuvant treatment) outpatient examination. We will then compare the difference in LVEF (LVEF 2-LVEF 1) measured in patients treated for left breast cancer with the difference in LVEF (LVEF 2-LVEF 1) measured in patients treated for right breast cancer
from one to six years from adjuvant radiotherapy for early breast cancer
No
Tanja Marinko, MD
Principal Investigator
Institute of Oncology Ljubljana
Slovenia: Ministry of Health
eHER2-TM
NCT01572883
December 2011
October 2012
Name | Location |
---|